| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
As a chemical intermediate, Taltobulin intermediate-3 does not have a biological target itself. Its final product, Taltobulin, targets tubulin (microtubules). Taltobulin disrupts tubulin polymerization, which inhibits cell division by preventing the formation of the mitotic spindle during the M phase of the cell cycle. This leads to mitotic arrest and induces apoptosis in cancer cells. The intermediate contributes to the final compound's ability to exert these anti-tumor effects.
|
|---|---|
| ln Vitro |
The in vitro activity is attributed to the final compound Taltobulin, not the intermediate. Taltobulin is a potent tubulin polymerization inhibitor, which arrests cells in the mitotic phase (M phase) of the cell cycle. It induces apoptosis in a variety of cancer cell lines, often with IC50 values in the low nanomolar to sub-nanomolar range. The intermediate is a synthetic precursor used in the assembly of Taltobulin and does not itself possess these biological activities.
|
| ln Vivo |
The in vivo activity is attributed to the final product Taltobulin, not the intermediate. Taltobulin, when conjugated to an antibody in an ADC or used alone, has been studied in animal models of cancer. It has demonstrated anti-tumor efficacy by disrupting microtubule dynamics, inducing mitotic arrest, and triggering apoptosis. Taltobulin intermediate-3 is a chemical building block used to synthesize the Taltobulin payload for these preclinical oncology studies and ADC development.
|
| Enzyme Assay |
There is no standard cell-free enzyme binding assay for the intermediate, as it is not a biologically active agent. The activity is assessed for the final product, Taltobulin. For Taltobulin, a standard microtubule/tubulin polymerization assay is performed. Tubulin is purified from bovine brain. The reaction mixture contains tubulin, GTP, and the test compound (Taltobulin or vehicle). Polymerization of tubulin into microtubules is monitored by measuring the increase in absorbance at 340 nm over time at 37degC. Taltobulin prevents microtubule formation, resulting in a reduced rate of absorbance increase. The half-maximal inhibitory concentration (IC50) can be determined.
|
| Cell Assay |
There are no standard cell-based assays for Taltobulin intermediate-3, as it lacks biological activity. However, for the final product Taltobulin, typical in vitro cytotoxicity assays are performed. Cancer cells (e.g., HeLa, HCT-116, A549) are seeded in 96-well plates and treated with varying concentrations of Taltobulin (or an ADC containing Taltobulin) for 48-72 hours. Cell viability is measured by MTT or CellTiter-Glo assay to determine the half-maximal inhibitory concentration (IC50). Cell cycle analysis is performed by propidium iodide staining and flow cytometry to detect the accumulation of cells in G2/M phase. Apoptosis is confirmed by Annexin V/PI staining and Western blot for cleaved caspase-3 and PARP.
|
| Animal Protocol |
Taltobulin intermediate-3 is not used directly in animal experiments. However, the final product (Taltobulin or an ADC containing Taltobulin) can be tested in vivo. For an ADC, a mouse xenograft model of a relevant cancer type (e.g., with a specific tumor-associated antigen) is established. Immunodeficient mice are implanted subcutaneously with cancer cells (e.g., 5 × 10⁶ cells/mouse). Once tumors reach ~100 mm3, mice are treated with the ADC (at doses of 1-10 mg/kg, intravenous injection, every 4-7 days) or vehicle control. Tumor volume and body weight are monitored. Efficacy is measured by tumor growth inhibition (TGI). Taltobulin intermediate-3 is a synthetic intermediate used in the production of Taltobulin for these studies.
|
| ADME/Pharmacokinetics |
Taltobulin intermediate-3 has a molecular weight of 235.75 and a molecular formula of C11H22ClNO2. It is a hydrochloride salt, which improves its stability and solubility. The compound is intended as a synthetic intermediate, not a final pharmaceutical, so detailed pharmacokinetic properties (half-life, bioavailability, clearance) are not reported. For use in synthesis, it is typically stored as a solid at -20degC. It is a building block in the synthesis of Taltobulin, which is a common toxin component in ADC preparation (ADC Cytotoxin).
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Taltobulin intermediate-3 is not available, as it is not a final therapeutic agent. The final compound, Taltobulin, is a potent tubulin inhibitor and is therefore highly toxic to dividing cells (such as cancer cells and normal proliferating cells). Based on its mechanism, Taltobulin can cause significant cytotoxicity, and it is classified as a cytotoxic agent (ADC cytotoxin). The intermediate is a synthetic precursor and should be handled with caution using appropriate laboratory safety procedures, including the use of gloves, goggles, and a lab coat.
|
| References |
[1]. Loganzo F, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res. 2003 Apr 15;63(8):1838-45.
|
| Additional Infomation |
Taltobulin intermediate-3 (CAS 610786-69-1) is a key intermediate in the synthesis of Taltobulin, a powerful tubulin inhibitor that disrupts tubulin polymerization, induces mitotic arrest, and induces apoptosis. Taltobulin is used as a common toxin component in the preparation of antibody-drug conjugates (ADCs) for targeted cancer therapy. ADCs consist of a tumor-targeting antibody linked to a cytotoxic payload (such as Taltobulin) via a linker, allowing for selective delivery of the toxin to cancer cells. Taltobulin intermediate-3 is essential for medicinal chemistry workflows focused on synthesizing targeted chemotherapeutics and ADC payload-linker systems. It is strictly for research use.
|
| Molecular Formula |
C11H22CLNO2
|
|---|---|
| Molecular Weight |
235.75
|
| Exact Mass |
235.133
|
| CAS # |
610786-69-1
|
| PubChem CID |
86593125
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
15
|
| Complexity |
209
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl[H].O(C([H])([H])C([H])([H])[H])C(C(C([H])([H])[H])=C([H])C([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([H])([H])[H])=O
|
| InChi Key |
DOGUQADNNOKYBX-NZPHSXCUSA-N
|
| InChi Code |
InChI=1S/C11H21NO2.ClH/c1-6-14-11(13)9(4)7-10(12-5)8(2)3;/h7-8,10,12H,6H2,1-5H3;1H/b9-7+;/t10-;/m1./s1
|
| Chemical Name |
ethyl (E,4S)-2,5-dimethyl-4-(methylamino)hex-2-enoate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2418 mL | 21.2089 mL | 42.4178 mL | |
| 5 mM | 0.8484 mL | 4.2418 mL | 8.4836 mL | |
| 10 mM | 0.4242 mL | 2.1209 mL | 4.2418 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
